Financial Analysis: Evofem Biosciences (NASDAQ:EVFM) versus ObsEva (NASDAQ:OBSV)

Profitability

This table compares Evofem Biosciences and ObsEva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
ObsEva	N/A	-416.36%	-92.01%

Valuation and Earnings

This table compares Evofem Biosciences and ObsEva”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39 million	0.10	$52.98 million	($0.06)	-0.15
ObsEva	N/A	N/A	-$58.38 million	($0.92)	N/A

Evofem Biosciences has higher revenue and earnings than ObsEva. Evofem Biosciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by company insiders. Comparatively, 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Evofem Biosciences has a beta of -1.34, indicating that its share price is 234% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.